Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 860 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Long-term Follow-up Clear all
Terminated No phase listed Observational

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

NCT00255645
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
165
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 162 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2008 · Synced Oct 23, 2026, 2:32 AM EDT
Not yet recruiting Phase 2 Interventional

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

NCT07581405
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer
Interventions
Neoadjuvant chemotherapy, Olanzapine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Enrolling by invitation Phase 3 Interventional

A Long-term Follow-up Study in Participants Who Received CTX001

NCT04208529
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2039
U.S. locations
9
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Completed No phase listed Observational

Follow up Study of Diaphragm Pacing for Patients With High Tetraplegia

NCT01815554
View directory record Official record
Conditions
Tetraplegia, Spinal Cord Injury
Interventions
Not listed
Lead sponsor
Craig Hospital
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 23, 2026, 2:32 AM EDT
Completed No phase listed Observational

Dark Adaptation in Participants With Age-Related Macular Degeneration

NCT03225131
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Completed No phase listed Observational

Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

NCT01393483
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma
Interventions
serum and tissue mesothelin
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 23, 2026, 2:32 AM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

NCT07503613
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Not listed
Lead sponsor
Akouos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Recruiting Phase 1 Interventional

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

NCT02852213
View directory record Official record
Conditions
AADC Deficiency
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
24 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
3
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Study of Tocilizumab to Treat Polymyalgia Rheumatica

NCT01396317
View directory record Official record
Conditions
Polymyalgia Rheumatica (PMR)
Interventions
Tocilizumab
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 23, 2026, 2:32 AM EDT
Active, not recruiting Not applicable Interventional

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

NCT01494324
View directory record Official record
Conditions
Liver Cancer
Interventions
CT guided percutaneous ablation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Memory Modulation in Nicotine Addiction

NCT03744559
View directory record Official record
Conditions
Nicotine Use Disorder
Interventions
Retrieval Extinction Training (RET), Control Retrieval Extinction Training (RET)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
25 Years to 65 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 23, 2026, 2:32 AM EDT
Completed Phase 4 Interventional Results available

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

NCT01409434
View directory record Official record
Conditions
Drug Induced Hyperglycemia, Secondary Hyperlipidemia
Interventions
Oral Glucose Tolerance Test
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 23, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00337285
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions
Vyvanse (lisdexamfetamine dimesylate), NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 23, 2026, 2:32 AM EDT
Terminated Phase 3 Interventional

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

NCT00827008
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
Neramexane mesylate
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Tucson, Arizona • Burbank, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 23, 2026, 2:32 AM EDT
Active, not recruiting No phase listed Observational

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

NCT06162585
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy product-MCO-010
Biological
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 23, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

NCT00413699
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
147
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 23, 2026, 2:32 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff Disease

NCT06614569
View directory record Official record
Conditions
GM2 Gangliosidosis, Tay Sachs Disease, Sandhoff Disease
Interventions
AXO-AAV-GM2
Drug
Lead sponsor
Terence Flotte
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 23, 2026, 2:32 AM EDT
Terminated No phase listed Observational

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

NCT04349956
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
UBX0101 or placebo
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
17
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 23, 2026, 2:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

NCT05366751
View directory record Official record
Conditions
Essential Tremor
Interventions
SAGE-324
Drug
Lead sponsor
Sage Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Hoover, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 23, 2026, 2:32 AM EDT
Recruiting No phase listed Observational

Long-term Follow-up of Subjects Treated With CAR T Cells

NCT05024175
View directory record Official record
Conditions
Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
Interventions
Disease assessments, Tumor Biopsy, Blood test
Diagnostic Test · Procedure
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Active, not recruiting Not applicable Interventional

Nurturing Care Family Navigator

NCT06859372
View directory record Official record
Conditions
Food Insecurity Among Children, Food Insecurity in Post Partum Women, Care Coordination in Primary Care, Preventive Care / Anticipatory Guidance, Retention in Care
Interventions
Nurturing Care Family Navigator
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 23, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

NCT00359619
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
CervarixTM, HPV investigational vaccine GSK568893A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 23, 2026, 2:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Sleep Restriction on Performance in Adults

NCT02960776
View directory record Official record
Conditions
Sleep, Obesity, Sleep Restriction
Interventions
Sleep Restriction (SR)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 23, 2026, 2:32 AM EDT